3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
4
Sarcoma
2
Head & Neck
2
Breast
2
Thoracic
1
Myeloid
1
Lymphoid
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Conditions
Melanoma
12
Lymphoma, T-Cell, Cutaneous
5
Mycosis Fungoides
4
Sezary Syndrome
3
Lung Neoplasms
3
Endometrial Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Uveal Melanoma
2
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Ovarian Neoplasms
2
Multiple Myeloma
2
Lymphoma, T-Cell
2
Carcinoma, Renal Cell
2
Carcinoma, Merkel Cell
2
Carcinoma, Hepatocellular
2
Uterine Neoplasms
1
Urogenital Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Interventions
pembrolizumab
27
Nivolumab
20
atezolizumab
6
Ipilimumab
6
Magnetic Resonance Spectroscopy
5
Specimen Handling
4
Paclitaxel
4
Docetaxel
4
Cyclophosphamide
4
Carboplatin
4
fludarabine
3
avelumab
3
Pemetrexed
3
Interleukin-2
3
tislelizumab
2
epacadostat
2
durvalumab
2
aldesleukin
2
Taxes
2
Radiosurgery
2
Cisplatin
2
veliparib
1
toripalimab
1
spartalizumab
1
sotigalimab
1
sonidegib
1
sargramostim
1
regorafenib
1
poly ICLC
1
liposomal doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
Immunoglobulin G
×
Dermatologic
×
Clear all
NCT05269381
2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2
Recruiting
132 enrolled